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membrane clearance of RNF43/ZNRF3, promote Wnt receptor stabilization and enhance Wnt responsiveness of stem cell populations [6] [7] [8] [9] [10] [11] [12] [13] .
Mutational loss of RNF43 and/or ZNRF3 is observed in human malignancies of the colon, pancreas, stomach, ovary, endometrium and liver [14] [15] [16] [17] [18] [19] [20] . Inactivation of RNF43/ZNRF3mediated feedback leads to an increased abundance of Wnt receptors at the cell surface, which renders cells hypersensitive to Wnt ligands in their environment 5 . The resulting Wntdependent growth state drives tumorigenesis and generates a druggable addiction to Wnt ligands in these cancer subsets 5, 15, 17, 18, 21, 22 . Indeed, blocking Wnt ligand biogenesis by small molecule inhibitors of the O-acyltransferase Porcupine (PORCN) suppresses the growth of RNF43-deleted pancreatic and small intestinal tumors in preclinical models 15, 23, 24 . This vulnerability has offered an opportunity to treat human cancers that are genetically defined by RNF43 mutations with Porc inhibitors. Currently, four small-molecule PORCN inhibitors are evaluated in clinical trials for cancer treatment (ClinicalTrials.gov, NCT01351103, NCT02278133, NCT02521844, NCT03447470, NCT02675946, and NCT03507998).
Clearly, mutational inactivation of RNF43 is a prerequisite for Wnt-dependent growth 23 . Recent cancer genome sequencing efforts, however, revealed a large diversity of genetic lesions within the RNF43 locus of various human cancer types (cBioportal.org) 25 .
This mutational variability poses a challenge to unambiguously distinguish driver from passenger mutations and predict which mutations truly generate a Wnt-dependent growth state that can be exploited by targeted treatment. Insight in the mechanisms by which individual RNF43 mutations contribute to cancer development and progression therefore is vital for the understanding of patient-specific disease mechanisms and the development of precision oncology strategies.
Here, we uncover a class of RNF43 truncating mutations that drive inappropriate Wnt pathway activation by a mechanism distinct from RNF43 LOF mutations. Through trapping of Casein kinase 1 (CK1) at the plasma membrane, these RNF43 mutants interfere with the turnover of the transcriptional coactivator -catenin, promoting the transcriptional activation of Wnt target genes. When introduced in primary human colon stem cells, truncated RNF43 mutants induce a state of oncogenic stress and require prior inactivation of TP53 to drive a niche-independent program for self-renewal and proliferation. Importantly, oncogenic RNF43 mutations, unlike conventional LOF RNF43 mutations, confer resistance to anti-Wnt-based therapy. Our results reveal the functional heterogeneity of cancer driver mutations in a single gene and demonstrate the importance of examining patient-derived mutations to uncover disease mechanisms, allow for improved patient stratification and applications of targeted therapy.
Results

Loss of the C-terminus endows the tumor suppressor RNF43 with oncogenic properties
RNF43 comprises a single-span transmembrane E3 ubiquitin ligase of 783 amino acids ( Fig. 1a ). Binding and ubiquitination of Wnt receptors maps to the N-terminal half of the RNF43 protein, including the extracellular (ECD), transmembrane (TM) and RING domains. These domains are followed by an extended C-terminal tail that contains conserved Ser-, His-, and Pro-rich regions to which no role has been assigned ( Fig. 1a) . Notably, a third of reported RNF43 cancer variants comprise nonsense or frameshift mutations that prospectively yield expression of C-terminally shortened RNF43 proteins for which functional consequences remain unknown (cBioportal.org) 20, 25 . To address this issue, we expressed RNF43 cancer variants carrying incremental C-terminal truncations in HEK293T cells and monitored their impact on Wnt-induced -catenin-mediated transcription. Strikingly, RNF43 variants truncated between residues K514-Q563 strongly induced -catenin-mediated transcription, independent of supplementation with Wnt ( Fig. 1b) . Unlike a well-defined LOF missense variant (I48T) 26 , these RNF43 mutants fully retained their ability to downregulate FZD receptors while strongly increasing cytosolic -catenin levels ( Fig. 1c-f ). Wnt pathway activation by the representative truncated RNF43 variant R519X remained unaffected by PORCN inhibitors 24 , while these compounds fully suppressed Wnt signalling activity induced by the LOF cancer mutant I48T or by RNF43/ZNRF3 deletion ( Fig. 1g , Supplementary Fig.   1a ) 15 . Thus, in contrast to LOF mutations, RNF43 R519X induces pathway activation in a ligand-independent manner. Furthermore, RNF43 R519X strongly induced Wnt pathway activation in an RNF43/ZNRF3-knockout background, indicating that these mutants do not operate via a dominant-negative mechanism ( Supplementary Fig. 1a ). Thus, truncated RNF43 variants gain competence to drive basal Wnt signalling and are functionally distinct from classical LOF mutations.
Premature termination codons within the oncogenic region of RNF43 avoid nonsensemediated decay
More precise mapping using designed RNF43 truncations showed that truncations within a region ranging from D504-Q563 unleash β-catenin-mediated transcription, indicating that oncogenic activity requires retention of the Ser-rich region and loss of the His-and Prorich regions (Fig 1b, Supplementary Fig. 1b ). Mutations introducing premature termination codons (PTC) within this RNF43 region occurred in various cancer types, including pancreas, endometrium, ovarium and colon (Supplementary Table 1 ). Expression of inappropriately truncated proteins is commonly limited due to nonsense-mediated decay mRNA surveillance pathways 27, 28 . To investigate this issue, we employed CRISPR/Cas9 to introduce biallelic RNF43 PTCs in SW480 APC-mutant colorectal cancer cells, in which RNF43 is actively transcribed ( Supplementary Fig. 1c, d ). Mutant RNF43 mRNAs (V520fs/D516fs) were expressed even at increased abundance compared to parental cells ( Supplementary Fig. 1e , f), indicating that these transcripts are stable and give rise to a protein product that promotes transcription via a feedforward mechanism.
Truncated RNF43 cancer variants interfere with downstream Wnt signalling events
Next, we aimed to identify the molecular requirements for the oncogenic activity of truncated RNF43 variants. Conventional wild-type RNF43 tumour suppressor activity relies on the RING-type E3 ligase domain that marks FZD for ubiquitin-mediated endocytosis and lysosomal turnover ( Fig. 1c, d) 4, 5 . The introduction of RING domain-inactivating mutations still allowed for RNF43 R519X-mediated induction of basal -catenin transcription, while responses to Wnt were further enhanced, likely due to the FZD stabilising effects of this catalytically inactive RNF43 variant ( Fig. 2b ) 5 . Furthermore, RNF43 R519X retained its ability to drive basal Wnt pathway activation when the ECD and TM domains were substituted by those of the unrelated transmembrane proteins CD16 and CD7 ( Fig. 2a , c).
Similar replacements in full-length RNF43 resulted in failure to downregulate FZD5 and loss of Wnt inhibitory activity ( Fig. 2c) 29 . Thus, the truncated RNF43 cytosolic tail is required and sufficient to drive oncogenic β-catenin-dependent transcription by a mechanism independent of the ECD and RING domains. In line with this, RNF43 R519X-induced -catenin transcription was insensitive to expression of Dishevelled (Dvl)-1 DEP-C, a Dvl fragment that binds the FZD cytosolic domains and blocks Wnt-mediated receptor activity ( Fig. 2d) 30 . In addition, signalling induced by ectopic expression of -catenin was unaffected by RNF43 R519X ( Fig. 2e ). We conclude that truncated RNF43 cancer variants affect a molecular step positioned downstream of the Wnt receptors and upstream of -catenin-mediated transcription.
Truncated RNF43 variants retain CK1 at the plasma membrane to drive -cateninmediated transcription
We next investigated if truncated RNF43 interferes with the -catenin destruction complex, which provides a central point for Wnt pathway regulation and is commonly targeted by inactivating mutations in cancer 31, 32 . BioID proximity labeling revealed interactions of WT RNF43 with destruction complex members Axin1, CK1, CK1 and APC ( Fig. 3a , Supplementary Table 2 ). Strikingly, interactions of truncated oncogenic RNF43 variants with endogenous Axin1, and CK1/ were increased in comparison to RNF43 WT ( Fig. 3b , Supplementary Fig. 2a ), while interactions with APC and GSK3 were not noticeably altered or even decreased ( Fig. 3b , Supplementary Fig. 2b , c). Moreover, expression of RNF43 R519X, but not WT or the non-oncogenic R371X variant, prompted a redistribution of Axin1, as well as endogenous CK1 and CK1, from cytosol to the plasma membrane ( Fig. 3c, d , Supplementary Fig. 2d , e). The interaction of CK1/ and RNF43 remained unaffected by depletion of Axin1 and its close homologue Axin2 ( Supplementary   Fig. 2f ), suggesting that CK1 interacts directly with the RNF43 cytosolic tail. Binding of CK1/ mapped to an intermittent region in the RNF43 C-terminus, composed of S486-Q488 and G492-S494 ( Supplementary Fig. 2g , h). Moreover, levels of CK1 binding correlated with Wnt pathway-activating ability of RNF43 R519X ( Supplementary Fig. 2h , i). These findings imply that retention of CK1 by RNF43 truncated cancer variants is essential for their oncogenic mode of action.
CK1-mediated phosphorylation of the RNF43 cytosolic tail confers oncogenic Wnt pathway activation
To investigate whether RNF43 is a target for CK1-mediated Ser/Thr phosphorylation, we analysed the phosphorylation status of RNF43 WT and R519X. Indeed, phosphorylation of RNF43 R519X was markedly increased when compared to RNF43 WT, consistent with its ability to trap endogenous CK1 (Supplementary Table 3 ). Phosphorylation of WT RNF43 was increased upon co-expression of CK1, but not CK1, suggesting that CK1 is the preferred kinase for functional cooperation. We identified a non-canonical CK1 SLSS target sequence at residues 500-503, which when truncated, abolishes oncogenic activity of RNF43 ( Supplementary Fig. 1b ). Ala substitution of the SLSS motif (SLSS>ALAA) in full-length RNF43 abolished pathway suppression, while introduction of phospho-mimetic residues (SLSS>DLDD) promoted suppressor activity, indicating that WT RNF43 normally employs CK1 kinase activity to perform its tumour suppressor role ( Supplementary Fig. 2j ). In accordance, an RNF43 cancer variant carrying a CK1 binding site deletion (ΔS486-G489>R; cBioportal) displayed LOF effects ( Supplementary Fig. 2j ). Introduction of SLSS>ALAA or CK1 binding site deletion fully abrogated the capacity of RNF43 R519X to induce basal Wnt pathway activation, while SLSS>DLDD R519X mediated increased tumourigenic activity ( Fig. 3e ). Thus, truncated RNF43 employs CK1 binding and phosphorylation to drive oncogenic Wnt pathway activation.
Oncogenic RNF43 mutations induce a TP53-dependent growth arrest in human colon organoids
Next, we investigated the impact of oncogenic RNF43 truncations on epithelial homeostasis, using human colon organoids 33, 34 . Introduction of CRISPR/Cas9-mediated frame shift mutations within the endogenous RNF43 locus (onco-RNF43) yielded only a limited number of small organoid clones that failed to thrive, reminiscent of a senescent phenotype ( Supplementary Fig. 1c , 3a) 35 . Genotyping of a slowly expanding clone confirmed the presence of a mono-allelic onco-RNF43 mutation ( Supplementary Fig. 3b ). This phenotype is strikingly different from RNF43 LOF mutations that are well tolerated in intestinal organoids 5, 36 . We wondered how onco-RNF43 induces epithelial growth arrest. In line with our model of onco-RNF43-mediated CK1 sequestration, ablation of Csnk1a1 (CK1) from the mouse intestinal epithelium was shown previously to trigger massive Wnt pathway activation accompanied with p53-mediated cellular senescence 37 . Combined ablation of Csnk1a1 and Tp53 instigated formation of highly invasive carcinomas 37 . Similarly, we noted a co-occurrence of oncogenic RNF43 frameshift mutations with mutations in TP53 or senescence-associated genes in human cancer (Supplementary Table 1 ), suggesting that TP53 inactivation might be required to bypass an oncogenic stress-induced growth arrest. Indeed, combined onco-RNF43/TP53KO mutant clones rapidly appeared after CRISPR/Cas9 targeting, thrived in large numbers and allowed for the occurrence of bi-allelic onco-RNF43 mutations ( Supplementary Fig. 3a, b ). Thus, loss of TP53 creates a permissive cellular state for onco-RNF43 expression.
Onco-RNF43 variants drive niche-independent growth in human colon organoids and confer resistance to anti-Wnt-based therapy
A key feature of cancer pathway driver mutations is their ability to confer nicheindependent growth, which is examined by depleting stem cell growth factors from the organoid culture medium 1, 34 . We wondered if the ability of onco-RNF43 to drive basal βcatenin-mediated transcription alleviates the need for supplementation of colon organoids with Wnt and/or R-spondin (Rspo), a Wnt-potentiating niche factor that induces membrane clearance of RNF43/ZNRF3 and allows for enhanced Wnt responsiveness of stem cell populations [6] [7] [8] [10] [11] [12] 38 . Omitting Wnt readily compromised viability of both WT and TP53KO organoid lines, as reported earlier 34, 39 , while onco-RNF43/TP53KO organoid growth remained unaffected ( Fig. 4a ). Although instant removal of Rspo was not tolerated by any of the organoid lines, onco-RNF43/TP53KO organoids displayed much greater tolerance to a step-wise decrease in Rspo concentrations when compared to WT and TP53KO organoid lines ( Fig. 4a ). We conclude that onco-RNF43 mutations confer decreased dependence on Wnt and Rspo niche factors, a hallmark of cancer cell growth.
To investigate the impact of onco-RNF43 mutations on gene expression in colon epithelial cells, we performed RNA sequencing of WT, TP53KO and onco-RNF43/TP53KO organoid lines grown in high Wnt/Rspo (20%) or no Wnt/low Rspo (0.2%) medium. Unsupervised clustering of significantly changing genes revealed four distinct clusters of gene expression dynamics ( Supplementary Fig. 4a ). Onco-RNF43-mediated transcriptome alterations were markedly enhanced in no Wnt/low Rspo growth conditions ( Supplementary   Fig. 4a, b ). Therefore, we focused on 1448 genes that were differentially expressed in TP53KO versus onco-RNF43/TP53KO organoid lines grown in no Wnt/low Rspo ( Supplementary Fig. 4a, b ). Of the 966 downregulated genes in onco-RNF43/TP53KO organoids, a minor group of 123 genes was traced back to loss of TP53. The remaining 843 genes were specifically and consistently downregulated by onco-RNF43 expression.
Conversely, 482 genes were significantly increased in onco-RNF43-expressing organoids.
Noticeably, this gene set was also upregulated in high Wnt/Rspo-treated organoids ( Supplementary Fig. 4a , right heatmap), indicating that onco-RNF43 confers a signature normally provided by the stem cell niche. Gene set enrichment analysis (GSEA) using MSigDB 40 revealed significant enrichment for Myc and E2F targets, Wnt signalling, DNA damage response and cell division by onco-RNF43 expression ( Fig. 4b) . A lentiviral Wnt GFP reporter 41 confirmed sustained Wnt signalling in onco-RNF43-expressing organoids in no Wnt/low Rspo growth conditions ( Fig. 4c ). Furthermore, differentiated cell type signatures 42 were lost in onco-RNF43-expressing organoids while profiles of transit amplifying cells were notably enriched ( Fig. 4d ). In summary, onco-RNF43 induces expression of a stem cell-like transcriptome in colonic epithelial cells and these effects are intensified in conditions where Wnt and Rspo are scarce.
The ability of onco-RNF43 mutations to drive Wnt-independent signalling stands in stark contrast to the previously described role of RNF43 LOF mutations that promote a Wntdependent growth state. Importantly, our findings predict differential sensitivity of these RNF43 mutational classes to treatment with PORCN inhibitors, Wnt antagonists that are currently evaluated for clinical treatment of RNF43-mutant cancer patients 3, [43] [44] [45] . Indeed, a large fraction of onco-RNF43/TP53KO organoid clones survived and recovered after one week of treatment with PORCN inhibitor C59, while no viable clones were obtained for WT and TP53KO organoids ( Fig. 5a, b ). Thus, onco-RNF43 expression confers resistance of human colon organoids to PORCN inhibitor treatment.
Discussion
Inappropriate Wnt/β-catenin signalling in cancer is achieved by two major mutational driver routes. Inactivation of the destruction complex is well-studied and exemplified by the prominent driver role of APC mutations in colorectal cancer 46 . More recently, misregulation of Wnt receptor abundance emerged as an alternative oncogenic pathway 3, 47 . RNF43 mutations, found in ~19% of colorectal cancer cases, are mutually exclusive to APC mutations and considered a prime hallmark of Wnt-hypersensitive cancer subsets 15, 20, 23 . Our study uncovers a class of RNF43 mutations that drive inappropriate Wnt pathway activation by a mechanism distinct from that of RNF43 LOF or APC mutations. By trapping CK1 at the membrane, these RNF43 mutants compromise -catenin destruction complex activity in the cytosol, leading to stabilisation of -catenin and the transcriptional activation of Wnt target genes ( Fig. 5c ). In support of their oncogenic role, the activity of these RNF43 variants does not require inactivation of the paralogue ZNRF3 5 . Different from APC mutations 48 , onco-RNF43 mutations induce a state of oncogenic stress in primary cells and require prior inactivation of TP53 to exert their oncogenic role.
In summary, we identified a class of RNF43 mutations that mediate a tumour suppressor-to-oncogene switch to drive downstream Wnt pathway activation. Unlike LOF mutations, the expression of onco-RNF43 variants predicts prolonged survival in Wntdepleted conditions and thus provides a contraindication for Wnt-or receptor-inhibiting treatment strategies. Our findings further imply that WT RNF43 performs a bifunctional tumour suppressor role, mediating ubiquitin-dependent Wnt receptor downregulation 4,5 as well as ubiquitin-independent regulation of destruction complex activity ( Fig. 5c ). Our study demonstrates the importance of examining patient-derived mutations to identify novel tumourigenic molecular mechanisms, obtain a broader comprehension of signalling pathways in normal and cancer cells and improve applications of precision cancer medicine.
METHODS
Cell culture and transfection
Human Embryonic Kidney (HEK) 293 cells, HEK293T cells and SW480 were cultured in RPMI or DMEM high glucose (Invitrogen), respectively, supplemented with 10% fetal bovine serum (GE Healthcare), 2 mM UltraGlutamine (Lonza), 100 units/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Cells were cultured at 37 °C in 5% CO2. Wnt3aconditioned medium (CM) was obtained from L-cells stably expressing and secreting Wnt3a 49 cultured in DMEM low glucose (Invitrogen). Rspo-and Noggin-CM were produced as described before 50 . For luciferase reporter assays, HEK293T cells were stimulated overnight (o/n) and for protein expression experiments cells were stimulated for 3 h with Wnt3a-CM.
Transfections were performed using FuGENE 6 (Promega) according to manufacturer's protocol. siRNA transfection was performed using Lipofectamine™ RNAiMAX (Thermo Fisher) according to manufacturer's protocol at 50nM for 4 days. Control (#1) siRNA were obtained from Ambion (Thermo Fisher) and the Axin1 SMARTpool of siRNA from Dharmacon (Horizon). For co-transfection, plasmids were transfected 1 day before analysis.
Plasmids and antibodies
Flag-Dishevelled1 DEP-C, TOPFlash and FOPFlash luciferase reporter plasmids were described previously 30, 49 . Myc-β-catenin and mouse Wnt3a were a kind gift of Hans Clevers (Hubrecht Institute, Utrecht, Netherlands). RNF43-2×Flag-HA and RING mutants were described previously 5 . Plasmid for expression of human Axin1-GFP was described previously 51 . All mutants were generated by either site-directed mutagenesis or by PCRsubcloning using Q5 High-Fidelity 2x Master Mix (NEB). All constructs were sequence verified. The following primary antibodies were used for immunoblotting (IB), Cells were homogenized by 25-50 strokes in a Douncer after which the homogenization was visually evaluated by microscopy. The homogenate was centrifuged at 500 x g at 4 °C for 10 min to obtain the nuclear pellet. The supernatant was subsequently centrifuged at 100.000 x g at 4 °C for 1 h to separate the membrane fraction from the cytosolic fraction.
Immunoblotting
Western blotting was performed using standard procedures with Immobilon-FL PVDF membranes (Millipore). In short: after protein transfer, the membranes were blocked for 1 h at RT in 1:1 ratio Odyssey blocking buffer (LI-COR): PBS. Primary antibodies were incubated o/n at 4 °C and secondary antibodies for 1 h at RT in the dark. The LI-COR Odyssey infrared imaging system was used for immunoblot analysis.
Immunofluorescence and SNAP labeling
HEK293T cells were grown on laminin-coated glass coverslips in 24-well plates and transfected after 24 h. For SNAP labeling, cells were labelled with 1 mM SNAP-surface 549 (Bioke) for 15 min at RT, washed and subsequently chased for 30 min at 37 °C. Cells were fixed in 4% paraformaldehyde or ice-cold methanol and blocked in PBS containing 2% BSA and 0.1% saponin. Primary and secondary antibody incubations were performed in blocking buffer for 45 min -1 h at RT. Cells were mounted in ProLong Gold (Life Technologies) and analysed using Zeiss LSM510 or LSM700 confocal microscope.
BioID for RNF43 interacting proteins
For the identification of RNF43 binding proteins a previously described protocol was used 52 .
Briefly, pcDNA4-TO-RNF43-BirA*-HA was obtained by cloning RNF43 into pcDNA3. 
Identification of phosphorylation sites by mass spectrometry
Briefly, cells were seeded in 15 cm dishes and transfected at 80% of confluency with the 
smRNA FISH
SW480 cells were grown on coverslips for 24 h. For smFISH, samples were prepared as previously described 54 . Briefly, cells were fixed for 10 min with 4% Formaldehyde solution (Sigma-Aldrich) and 70% Ethanol o/n. Samples were then hybridized with Quasar 670 labelled RNF43 probes (Stellaris, Biosearch Technologies) and mounted to microscopy slides using Prolong Diamond Antifade (Invitrogen). Images were acquired using a deconvolution system (DeltaVision RT; Applied Precision) using 60x lens.
gRNAs and genotyping
The pSpCas9(BB)-2A-Puro was obtained from Addgene (48139). gRNAs were generated as previously described 55 Wnt3a-CM and Rspo1-CM were adjusted. All experimentation using human organoids described herein was approved by the ethical committee at University Medical Center Utrecht (UMCU; TcBio #12-093). Informed consent for tissue collection, generation, storage, and use of the organoids was obtained from the patients at UMCU.
Organoid electroporation
Organoid electroporation was performed as previously described 56 . Briefly, organoids were grown in 10 M Y-27632 (Selleck chemicals) and 5 M CHIR 99021 (Tocris) without Wnt-conditioned media for 2 d before electroporation. 24 h before electroporation, 1.25% DMSO was added to the culture medium. For electroporation the NEPA21 electroporator was used with the configuration reported by Fujii et al. 56 . 10 g of pSpCas9(BB)-2A-Puro (PX459-#48139) was used to generate mutant lines. Organoids were recovered for 1 d by adding medium supplemented with 1.25% DMSO, 10 M Y-27632 and 5 M CHIR 99021 followed by another day with 10 M Y-27632 and 5 M CHIR 99021. 5 d post-electroporation organoids were grown in ENRW-Nic-A-S. For CRISPR-engineered organoids, single clones were established by manual picking of individual organoids derived from single cells and genotyped. PiggyBAC overexpressing organoids were selected using 50 g/L Hygromycin (Merck).To visualise Wnt activity, organoids were transduced with 7xTcf-eGFP:SV40-PuroR (Top-GFP) (Addgene #24305) 41 as described 57 and selected with Puromycin (Invivogen; 2 g/mL).
Clonogenic assay
Clonogenic assay was performed as previously described 58 . Briefly, WT, TP53KO and onco-RNF43/TP53KO organoid lines were mechanically dissociated for 5 minutes by using a narrow Pasteur pipette. At day 2 organoids were counted and C59 (Tocris; 1 M) was added for 7 days. At day 9 organoids were split and seeded in full medium and counted at day 14 (n = 3). Pictures were taken at day 2 and 14 using an Evos microscope.
RNA Sequencing
Organoids were grown in full medium or medium without Wnt and 0.2% Rspo medium for 48 h and were lysed in RLT lysis buffer (Qiagen). RNA was obtained using the Qiagen QiaSymphony SP (Qiagen) according to the manufacturer's protocol. Single-end reads of 75 bp were aligned to GRCh37 with STAR 59 with parameters outSJfilterIntronMaxVsReadN, chimJunctionOverhangMin and chimSegmentMin set to 10000000, 15 and 15, respectively.
Gene expression was quantified with edgeR with the human Ensembl transcript database version 74. Differential gene expression analysis was performed with DESeq2 60 , and its 'rlogTransformation' function was used for variance stabilisation of gene expression data.
Clustering and generation of heatmaps was done with ComplexHeatmap 61 . UpSet plots were created with the UpSetR R package 62 . Intestinal cell-type specific gene sets for Gene Set Enrichment Analysis (GSEA; http://www.broad.mit.edu/gsea/) were defined as the 250 most specific cell-type signature genes per cell-type from Extended Figure Table 3 of Haber et al. 42 . Human orthologues of each cell-type gene set were determined with the biomaRt R package 63 . To calculate the false discovery rate of every GSEA, we performed 10,000 gene set perturbations.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. The RNA-seq data are publicly available at the NCBI GEO repository (accession number GSE129288 
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